(Q47765380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

title

Drug repurposing may generate novel approaches to treating depression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

author name string

Mohamed Elsaed Ebada

series ordinal

1

1 reference

http://europepmc.org/abstract/MED/28925030

5 February 2018

publication date

18 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacy and Pharmacology

30 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

1428-1436

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

A rating scale for depression

30 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Depression in cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Depression in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Genetic Contributions of Inflammation to Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The vascular depression hypothesis: mechanisms linking vascular disease with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The catecholamine hypothesis of affective disorders: a review of supporting evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Dysregulated hypothalamic-pituitary-adrenal axis function contributes to altered endocrine and neurobehavioral responses to acute stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Glucocorticoid resistance in chronic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

A molecular and cellular theory of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Brain-derived neurotrophic factor: role in depression and suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Inflammation in Depression and the Potential for Anti-Inflammatory Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Peripheral Inflammatory Parameters in Late-Life Depression: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Mood disorders in the elderly: prevalence, functional impact, and management challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Clinically defined vascular depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Cerebral white matter is highly vulnerable to ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

A study of orthostatic hypotension, heart rate variability and baroreflex sensitivity in late-life depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Depressive-like behaviors in a rat model of chronic cerebral hypoperfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Relationship of endothelial function and atherosclerosis to treatment response in late-life depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Filling the gap in CNS drug development: evaluation of the role of drug repurposing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

In silico methods for drug repurposing and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Deconstructing the drug development process: the new face of innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Drug combination therapy increases successful drug repositioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Mechanisms of action of valproate: a commentatory

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Antidepressant-like effect of valproic acid-Possible involvement of PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Ketamine: repurposing and redefining a multifaceted drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Topical and peripheral ketamine as an analgesic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Ketamine as a fast acting antidepressant: current knowledge and open questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Sigma receptors: potential targets for a new class of antidepressant drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

N-acetylcysteine prevents stress-induced anxiety behavior in zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

How an age of anxiety became an age of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Do Statins Have Antidepressant Effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Metformin: repurposing opportunities for cognitive and mood dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

PPAR-γ Agonists for the Treatment of Major Depression: A Review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Pioglitazone could induce remission in major depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Therapeutic interventions for vascular depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

'Vascular depression' hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Efficacy of High-Dose Supplementation With Oral Vitamin D3 on Depressive Symptoms in Dialysis Patients With Vitamin D3 Insufficiency: A Prospective, Randomized, Double-Blind Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

The Nature and Determinants of Neuropsychological Functioning in Late-LifeDepression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12815

21 January 2018

Identifiers

DOI

10.1111/JPHP.12815

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28925030%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference